Earnings summaries and quarterly performance for Enovis.
Executive leadership at Enovis.
Board of directors at Enovis.
Research analysts who have asked questions during Enovis earnings calls.
Caitlin Cronin
Canaccord Genuity
4 questions for ENOV
Also covers: ATEC, AXGN, BVS +10 more
Danielle Antalffy
UBS Group AG
4 questions for ENOV
Also covers: ABT, ATRC, BAX +15 more
Vijay Kumar
Evercore ISI
4 questions for ENOV
Also covers: A, ABT, AVTR +21 more
Robert Marcus
JPMorgan Chase & Co.
3 questions for ENOV
Also covers: ABT, BAX, BDX +21 more
Vikramjeet Chopra
Wells Fargo & Company
3 questions for ENOV
Also covers: ALGN, ATEC, CNMD +9 more
Young Li
Jefferies
3 questions for ENOV
Also covers: ALC, ARAY, ATEC +8 more
Brandon Vazquez
William Blair & Company, L.L.C.
2 questions for ENOV
Also covers: ALGN, CBLL, CVRX +16 more
Dane Reinhardt
Robert W. Baird & Co.
2 questions for ENOV
Also covers: INMD
Jeffrey Johnson
Robert W. Baird & Co. Inc.
2 questions for ENOV
Also covers: ALC, ALGN, BBNX +11 more
Michael Matson
Needham & Company
2 questions for ENOV
Also covers: AORT, ATRC, CNMD +22 more
Russell Yuen
William Blair & Company
2 questions for ENOV
Also covers: ALGN, NVST
Jason Wittes
Roth Capital Partners, LLC
1 question for ENOV
Also covers: ALUR, ARAY, ATEC +13 more
Joseph Conway
Needham & Company, LLC
1 question for ENOV
Also covers: AORT, ATRC, HOLX +6 more
Mike Matson
Needham & Company, LLC
1 question for ENOV
Also covers: CNMD, ESTA, HAE +16 more
Vik Chopra
Wells Fargo & Company
1 question for ENOV
Also covers: ALGN, ATEC, CNMD +7 more
Recent press releases and 8-K filings for ENOV.
Enovis Discusses Strategic Focus, Growth Drivers, and Financial Goals at Jefferies Conference
ENOV
CEO Change
M&A
Guidance Update
- Damien McDonald, Enovis's newly appointed CEO, shared positive impressions of the company's strong product portfolio and talent, while highlighting the embedding of the Enovis Growth Excellence business system as a key opportunity.
- The company is actively shaping its portfolio, including the sale of the Dr. Comfort foot care business to improve capital allocation and debt reduction, which is expected to be accretive to the PNR business's growth and margin.
- Enovis is targeting high single-digit consistent top-line growth, annual margin expansion of at least 50 basis points, and free cash flow conversion of 70%-80%.
- Key growth drivers include 6%-7% implant growth in hips and knees, double-digit growth in shoulder and foot & ankle, and significant international expansion (nearly 50% of sales from 22%) following the LEMA integration.
- The company has reduced its leverage from 3.5 to 3.2 and aims to achieve sub-3 leverage in the near term.
Nov 18, 2025, 3:30 PM
Enovis Management Discusses Strategic Focus, Financial Goals, and Product Pipeline at Jefferies Conference
ENOV
Guidance Update
M&A
Product Launch
- Enovis's CEO, Damien McDonald, shared positive impressions regarding the company's strong product perception and talent, while identifying the deeper embedding of the Enovis Growth Excellence business system as a key opportunity.
- The company's strategic focus centers on commercial excellence, operational excellence, and disciplined capital allocation, highlighted by the Dr. Comfort divestiture, which was accretive to the PNR business's growth and margin and contributed to debt reduction.
- Enovis aims for high single-digit consistent top-line growth, annual margin expansion of at least 50 basis points, and free cash flow conversion up to 70-80%.
- The company has successfully reduced its leverage from 3.5 to 3.2 and is targeting a further reduction to sub-3 in the near term.
- Key product developments include the Ultamate Reverse Shoulder, which is in its early launch phase with a multi-year growth tailwind, and the Arvis Gen 2 AR headset, anticipated for a wider launch in the first half of next year.
Nov 18, 2025, 3:30 PM
Enovis Management Discusses Strategic Priorities, Portfolio Shaping, and Financial Goals at Jefferies Conference
ENOV
CEO Change
M&A
Product Launch
- CEO Damien McDonald, who joined mid-year, shared positive impressions of Enovis's product strength and talent, identifying an opportunity to further embed the Enovis Growth Excellence business system.
- The company is strategically shaping its portfolio, having divested the Dr. Comfort foot care business to reduce debt and enhance PNR's growth and margin. The portfolio is viewed as synergistic, with cash-generating PNR supporting the capital-intensive Recon business, aiming for a balanced mix in Recon (50% extremities, 50% large joints; 50% U.S., OUS).
- Enovis reported solid Ortho market procedural volumes for the current quarter, with U.S. hip and knee implants growing 6% (above market) despite a $3 million headwind from prior year capital sales, and double-digit growth in shoulder and foot and ankle.
- Innovation continues with key product launches like the Ultamate Reverse Shoulder (in its first year of a multi-year run) and the upcoming Arvis Gen 2 AR headset, which is a zero-footprint, low-cost alternative for surgical planning and navigation. These new products are expected to contribute to margin expansion.
- Financial goals include achieving high single-digit consistent top-line growth, expanding margins by at least 50 basis points annually, and reaching 70-80% free cash flow conversion. Leverage has been reduced from 3.5x to 3.2x, with a near-term target of sub-3x.
Nov 18, 2025, 3:30 PM
Enovis Outlines Strategic Priorities, Product Pipeline, and Financial Goals
ENOV
M&A
Product Launch
New Projects/Investments
- Enovis is currently focused on integrating the Lima acquisition, improving free cash flow generation (aiming for 70-80% conversion), and reducing its leverage ratio to under 3.0 from the current 3.2 before pursuing further strategic M&A.
- The company expects Arvis, a spatial navigation system for knees and shoulders, to be a significant tailwind, with a broader release planned for the first half of 2026.
- Enovis is seeing strong performance in its shoulder segment, with the augmented glenoid (ARG) product growing double digits through nine months, and is leveraging its market position in shoulder to gain share in hip and knee.
- The PNR business, while lower-growth, is a high cash flow generator that funds innovation in the capital-intensive recon business and has shown 110 basis points of gross margin improvement in the last quarter due to the application of the EGX business system.
Nov 10, 2025, 7:45 PM
Enovis Reports Strong Q3 2025 Results and Raises Full Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported Q3 2025 Net Sales of $549 Million, reflecting 9% reported growth and 7% organic growth, with Adjusted EPS reaching $0.75.
- The company generated approximately $30 Million in Free Cash Flow during Q3 2025, indicating improving cash generation.
- Enovis updated its Full Year 2025 outlook, raising guidance for aEBITDA to $395-$405 Million and aEPS to $3.10-$3.25.
- A divestiture of the Diabetic Footwear business, with a total transaction value of up to $60 Million and an upfront cash payment of $45 Million, is effective Q4 2025 and is expected to impact Q4 2025 revenue guidance by approximately ($15 Million).
Nov 6, 2025, 1:30 PM
Enovis Reports Q3 2025 Financial Results and Updates Full-Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported Q3 2025 sales of $549 million, marking a 9% reported and 7% organic growth, with strong performance in its recon business which grew 9% organically.
- The company completed the divestiture of its Doctor Comfort business in early October for up to $60 million, using $45 million in upfront cash to reduce debt and sharpen its focus on core markets.
- Full-year 2025 guidance was updated, with revenue adjusted to $2.24-$2.27 billion, adjusted EBITDA raised to $395-$405 million, and adjusted EPS increased by $0.05 to $3.10-$3.25.
- A non-cash technical impairment of goodwill totaling $548 million was recorded in Q3 2025 due to a sustained decline in share price, though it does not affect liquidity or future operations.
- Key product developments include the next-generation ARVIS Ultra system tracking for a broader launch in the first half of 2026, and new products like Nebula Stem and OrthoDrive Impactor performing well.
Nov 6, 2025, 1:30 PM
Enovis Announces Third Quarter 2025 Results and Updates Full-Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported net sales of $549 million for the third quarter of 2025, marking a 9% increase on a reported basis and 7% organically compared to the same period in 2024.
- The company posted a net loss of $571 million, or $9.99 per share, primarily due to a non-cash goodwill impairment charge of $548 million. Despite this, adjusted net earnings per diluted share were $0.75 and adjusted EBITDA was $95 million.
- In October 2025, Enovis completed the divestiture of its Diabetic Footcare business unit for up to $60 million, which resulted in a $15 million revenue reduction in the updated 2025 guidance.
- Enovis raised its full-year 2025 guidance for adjusted EBITDA to $395-405 million (from $392-402 million) and adjusted EPS to $3.10-3.25 (from $3.05-3.20). Revenue guidance was updated to $2.24-2.27 billion.
Nov 6, 2025, 11:09 AM
Enovis Announces Third Quarter 2025 Results and Updated Full-Year Guidance
ENOV
Earnings
Guidance Update
M&A
- Enovis reported third-quarter 2025 net sales of $549 million, reflecting a 9% reported growth and 7% organic growth compared to the same quarter in 2024.
- The company recorded a net loss of $571 million, or $9.99 per share, for the third quarter of 2025, which included a non-cash goodwill impairment charge of $548 million.
- For the third quarter of 2025, adjusted EBITDA was $95 million and adjusted net earnings per diluted share were $0.75.
- Enovis completed the divestiture of its Diabetic Footcare business unit in October 2025 for total proceeds of up to $60 million.
- The company raised its full-year 2025 adjusted EBITDA guidance to $395-405 million and adjusted EPS guidance to $3.10-3.25.
Nov 6, 2025, 11:01 AM
Enovis completes sale of Dr. Comfort diabetic shoe business
ENOV
M&A
New Projects/Investments
- Enovis™ Corporation sold its Dr. Comfort diabetic shoe business to Promus Equity Partners.
- The transaction is valued at up to $60 million in cash, consisting of an upfront payment of $45 million and up to $15 million payable in the future upon achieving certain milestones.
- This divestiture is intended to sharpen Enovis' focus on its core strengths in Prevention & Recovery, streamline its portfolio, and is expected to expand margins, enhance profitability, and accelerate debt reduction.
- Enovis will provide further strategic commentary on this transaction during its third quarter results call on Thursday, November 6th, at 8:30 am.
Oct 8, 2025, 12:15 PM
Enovis Discusses Growth Strategy, Financial Outlook, and Product Development at Baird Conference
ENOV
Guidance Update
Product Launch
New Projects/Investments
- Enovis's new CEO, Damien McDonald, is focusing on organic growth, strengthening the balance sheet, and expanding the recon business, particularly following the Lima acquisition. The U.S. hip and knee business is growing at 2x the market rate, aiming for upper single-digit growth.
- The company anticipates continued improvements in cash generation through 2025, with a significant "step forward" in 2026 due to reduced European Medical Device Regulation spend (from $16 million to almost zero), progress on Lima integration, and working capital efficiency.
- The net tariff headwind for 2025 is now estimated at $5 million-$10 million, a reduction from the initial $20 million guidance, with potential for further decrease in 2026. Enovis expects to maintain 50-75 basis points a year in operating margin expansion.
- The delayed introduction of ARVIS 2.0 means capital sales will remain a headwind through year-end 2025, with ramp-up expected in 2026 as the selling strategy shifts to flexible models. The CEO also expressed a desire to increase R&D spending from its current 5-6% of revenue.
Sep 10, 2025, 6:35 PM
Quarterly earnings call transcripts for Enovis.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more